Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

altRX vs EmbraceRX

altRX
Graded #93

Higher grade

vs+12.800000000000004
EmbraceRX
Graded #362

Lower grade

The verdict

altRX takes it — 71.4/100 to 58.6/100.

altRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuealtRX +29
74
45
Dose & formulationaltRX +21
77
56
Clinical oversightaltRX +6
82
76
Labs & monitoringaltRX +1
53
52
FulfillmentEven
73
73
Contract termsEven
55
55
altRX · left barEmbraceRX · right bar

The numbers

MetricaltRXEmbraceRX
WeighScore71.4/10058.6/100
GradeCC
Scorecard rank#93#362
Semaglutide$149/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
altRX

Graded #93 · C

Strengths

  • Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
  • LegitScript Certified with a publicly verifiable seal
  • Publishes the FDA compounded-medication disclaimer
  • Transparent pricing across all six product tiers (compounded plus four brand-name)
  • All-inclusive pricing — consult, prescription, and shipping with no hidden fees

Where it loses points

  • States-served list not disclosed
  • 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
  • 503A vs 503B designation not specified
  • No named medical director
  • Corporate physical address not disclosed
EmbraceRX

Graded #362 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard